\
&
Contact us
\
&
Contact us
Published on | 4 years ago
Programmes ERC MSCA RI EIC Horizon Europe ICT NMBP SPACE Food Climate/Environment Societies Security WideningThere are 11 attachments connected to this article.
Attachments are only accessible for people with an account on the NCP Flanders website.
The launch of the full Horizon Europe programme is now very close. In this article we provide you an overview of the current status. For each programme, the most recent available version is listed.
All mentioned work programmes can be downloaded through the attached files to this article.
Unless otherwise mentioned, it concerns draft versions, thus (minor) changes to the texts are still possible.
Pillar 1 - Excellent Science
Pillar 2 - Gobal Challenges and European Industrial Competitiveness
Pillar 3 - Innovative Europe
Widening Participation and Strengthening the European Research Area
In the very near future, these work programmes will be available on the domain specific pages on our NCP Flanders website.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Health Culture and society Security Digital, Industry & Space
The Norwegian University of Science and Technology (NTNU) has compiled a set of brochures, showcasing what NTNU's researchers can bring to the table on the topic of the six clusters within pillar II of the Horizon Europe programme. A seperate brochure covers the expertise NTNU can bring in the context of the 5 EU Missions. Through a mapping ex... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
